Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // January 10th, 2011 // 7:54 am
Welcome to another working week, everyone, and nice to see you again. We hope your weekend was refreshing and pleasant. Now, though, the time has come to resume the routine as those meetings and deadlines loom. To cope, we are brewing our mandatory cup of stimulation. As always, we invite you to join us. Meanwhile, here are some tidbits to help you get going. Have a great day and stay in touch…
Gilead Extends Length Of HIV Drug Study (Associated Press)
GlaxoSmithKline And Epizyme Sign Development Deal (The Boston Globe)
Lilly Pancreas Drug Questioned By FDA Staff (Reuters)
Sanofi-Aventis and Genzyme Still Have ‘Significant’ Differences (Bloomberg News)
J&J Bid For Smith & Nephew Wasn’t Disclosed (Reuters)
Genentech Sued Over Raptiva Links To Brain Disease (Bloomberg News)
Drug Recalls Worry Timber Pallet Makers (TTJ Online)
USP Wants Clearer Drug Labels (InPharma Technologist)
The New Roche Tower In Basel Will Look Like This (BD Online)
Pharmac Seeks Feedback On Patient Proposal (New Zealand Herald)
Opium, Alkaloids And Tasmanian Farmers (Sky News)
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
Alkaloids, Basel, Drug Recalls, Genentech, Genzyme, GlaxoSmithKline, Johnson & Johnson, New Zealand, Opium, Pallets, Pharmac, PML, Poppies, Raptiva, Roche, Sanofi Aventis, Smith & Nephew, Tasmania, US Pharmacopeia